ICT21

BTN3A agonist in auto-immune disorders

ICT21

About this program

This program aims to develop an antibody that antagonizes BTN3A for use in auto-immune disorders. By turning down previously activated γ9δ2 T cells, this anti-BTN3A should alleviate dysfunctional activation associated with chronic immune-mediated inflammation (IMI).
ImCheck Therapeutics has selected a lead antagonist anti-BTN3A candidate that inhibits γ9δ2 T cell activation and has partnered with world-class academic centers that have strong experience in IMI disorders including lupus, inflammatory bowel disease, and rheumatoid arthritis in order to position its therapeutic candidate in the IMI disease landscape.

Mechanism of action

ICT21